Trial Profile
Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ELOQUENT-2
- Sponsors Bristol-Myers Squibb
- 17 Jun 2022 Extended 3 year follow-up results assessing efficacy and safety of elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma, presented at the 27th Congress of the European Haematology Association.
- 07 Jun 2022 Results of an analysis the synthetic control arm potential of derived from EHR to provide additional support for trials investigating treatment efficacy in multiple myeloma presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 05 Oct 2021 This trial has been completed in Poland, according to European Clinical Trials Database